Advancing therapeutic bioconjugate discovery and manufacturing
A site-selective, orthogonal, and scalable bioconjugation technology for faster, more precise discovery and manufacturing of biologics
Incubating in Austin, TX
at ACC Bioscience Incubator
Protected by wholly owned IP (provisional patent filed)
Founded by researchers
from Scripps Research
and industry experts
[About Us]
[Our team]
We are a deep-tech biotechnology company
developing next-generation tools for site-specific bioconjugation.
Our mission is to give scientists full control
over where and how payloads are attached
— unlocking precision, speed, and scale
in biologics development.
Born out of rigorous scientific research and engineering principles, our team bridges the gap between biology and manufacturability, enabling what others cannot: robust, scalable expression of novel biomolecules
in a fraction of the time.
Published in Nature, Science, Cell,
Plexium founding team
Proposed and developed a POC
of the platform for optogenetic Nav1.7
drug screening in collaboration
with Vertex Pharmaceuticals inc.
Pavel Chubukov, PhD
Founder, stand-in CTO
Ph.D. Scripps Research
Connect
Program Manager, Construction Engineer
Naval Mobile Construction Battalion Platoon Commander
Public Works Officer, Deep Sea Diving Officer, Ocean Survey Officer at Navy Civil Engineer Corps
Datacenter Engineer, at Veterans Affairs National Datacenter Operations
and Logistics
Acquisition Liaison at the Bureau
of Ocean Energy Management
Benjamin Queener
Founder, interim CEO
St. Jude Children’s Research Hospital
Sr. Researcher: Hematology, Tsai Lab
Gene therapy technology development
1859 Advanced Research
Vertex Pharmaceuticals
partnership scientist
Plexium founding team
Yousif Slaiwa
Founder, Director
[Our science]
We believe bioconjugation should be engineered,
not improvised.
You know where the payload goes
— every time
Quantitative Site-selectivity
Compatible with other conjugation strategies without cross-reaction
Bio-Orthogonality
Faster lead molecule identification and production cycles
Speed & Efficiency
Eliminate guesswork, increase precision, and reduce cost
Homogeneity & Control
Contact our team
[Compared
to conventional methods]
[Our platform offers:]
Feature
Scalability
Yield
Site-specificity
Our Platform
Traditional Methods
Compatibility
Limited
Inconsistent
Hard
to reproduce
Limited
Precise
Robust
Designed for manufacturing
Orthogonal to other pathways
[Applications]
Our platform enables transformative capabilities across multiple therapeutic categories:
Antibody-drug conjugates
(ADCs)
Custom-bioconjugates
modified cytokines
therapeutic viral particles
manufacturable biosimilars
for short half life radionuclide delivery
Ultra-fast
payload conjugation
Let’s build
the next breakthrough together.
Contact us to explore collaboration.
Contact our team
[Careers]
We’re always looking
for talented scientists, engineers, and builders
who want to reimagine
what’s possible.
We don’t post traditional job openings, because we’re building something non-traditional.
If you’re excited by our mission, reach out
and tell us how you'd like to contribute.
Send your resume and note to info@nodon.bio or use the contact form below.
Share your details,
and we’ll gladly contact you to discuss your inquiries
or ideas.
[Contacts]
Antibody-drug conjugates
(ADCs)
Custom-bioconjugates
modified cytokines
therapeutic viral particles
manufacturable biosimilars
for short half life
radionuclide delivery
Ultra-fast
payload conjugation
We are a deep-tech biotechnology company
developing next-generation tools
for site-specific bioconjugation.
Our mission is to give scientists
full control over where and how payloads are attached — unlocking precision, speed, and scale
in biologics development.
Born out of rigorous scientific research and engineering principles, our team bridges the gap between biology and manufacturability, enabling what others cannot: robust, scalable expression of novel biomolecules in a fraction of the time.
[About Us]
[Our science]
We believe bioconjugation should be engineered, not improvised.
[Compared to conventional methods]
[Our platform offers:]
[Applications]
[Careers]
[Contacts]
Advancing therapeutic bioconjugate discovery and manufacturing
A site-selective, orthogonal, and scalable bioconjugation technology for faster, more precise discovery
and manufacturing of biologics
Contact us
Incubating in Austin, TX
at ACC Bioscience Incubator
Protected by wholly owned IP (provisional patent filed)
Founded by researchers
from Scripps Research
& industry experts
You know where the payload goes—every time.
Quantitative
Site-selectivity
Compatible with other conjugation strategies without cross-reaction.
Bio-Orthogonality
Faster lead molecule identification and production cycles.
Speed & Efficiency
Eliminate guesswork, increase precision, and reduce cost.
Homogeneity & Control
Our platform enables transformative capabilities across multiple therapeutic categories:
We’re always looking for talented scientists, engineers, and builders who want to reimagine
what’s possible.
Share your details, and we’ll gladly contact you to discuss your inquiries or ideas.
We don’t post traditional job openings,
because we’re building something non-traditional.
If you’re excited by our mission, reach out
and tell us how you'd like to contribute.
Send your resume and note to info@nodon.bio or use the contact form below
Let’s build the next breakthrough together.
Contact us to explore collaboration.
Feature
Compatibility
Scalability
Yield
Site-specificity
Our Platform
Traditional Methods
Limited
Inconsistent
Hard to reproduce
Limited
Precise
Robust
Designed for manufacturing
Orthogonal to other pathways
Published in Nature, Science, Cell
Plexiumfounding team
Proposed and developed a POC
of the platform for optogenetic Nav1.7
drug screening in collaboration
with Vertex Pharmaceuticals inc.
Pavel Chubukov, PhD
Founder, stand-in CTO
Ph.D. Scripps Research
Program Manager, Construction Engineer
Naval Mobile Construction Battalion Platoon Commander
Public Works Officer, Deep Sea Diving Officer, Ocean Survey Officer at Navy Civil Engineer Corps
Datacenter Engineer, at Veterans Affairs National Datacenter Operations and Logistics
Acquisition Liaison at the Bureau of Ocean Energy Management
Benjamin Queener
Founder, interim CEO
St. Jude Children’s Research Hospital
Sr. Researcher: Hematology, Tsai Lab
Gene therapy technology development
1859 Advanced Research
Vertex Pharmaceuticals
partnership scientist
Plexium founding team
Yousif Slaiwa
Founder, Director
Antibody-drug conjugates
(ADCs)
Custom-bioconjugates
modified cytokines
therapeutic viral particles
manufacturable biosimilars
for short half life
radionuclide delivery
Ultra-fast
payload conjugation
We are a deep-tech biotechnology company
developing next-generation tools
for site-specific bioconjugation.
Our mission is to give scientists
full control over where and how payloads are attached — unlocking precision, speed, and scale
in biologics development.
Born out of rigorous scientific research and engineering principles, our team bridges the gap between biology and manufacturability, enabling what others cannot: robust, scalable expression of novel biomolecules in a fraction of the time.
[About Us]
[Our science]
We believe bioconjugation should be engineered, not improvised.
[Compared to conventional methods]
[Our platform offers:]
[Applications]
[Careers]
[Contacts]
Advancing therapeutic bioconjugate discovery and manufacturing
A site-selective, orthogonal, and scalable bioconjugation technology for faster, more precise discovery
and manufacturing of biologics
Contact us
Incubating in Austin, TX
at ACC Bioscience Incubator
Protected by wholly owned IP (provisional patent filed)
Founded by researchers
from Scripps Research
& industry experts
You know where the payload goes—every time.
Quantitative
Site-selectivity
Compatible with other conjugation strategies without cross-reaction.
Bio-Orthogonality
Faster lead molecule identification and production cycles.
Speed & Efficiency
Eliminate guesswork, increase precision, and reduce cost.
Homogeneity & Control
Our platform enables transformative capabilities across multiple therapeutic categories:
We’re always looking for talented scientists, engineers, and builders who want to reimagine
what’s possible.
Share your details, and we’ll gladly contact you to discuss your inquiries or ideas.
We don’t post traditional job openings,
because we’re building something non-traditional.
If you’re excited by our mission, reach out
and tell us how you'd like to contribute.
Send your resume and note to info@nodon.bio or use the contact form below
Let’s build the next breakthrough together.
Contact us to explore collaboration.
Contact our team
Feature
Compatibility
Scalability
Yield
Site-specificity
Our Platform
Traditional Methods
Limited
Inconsistent
Hard to reproduce
Limited
Precise
Robust
Designed for manufacturing
Orthogonal to other pathways
Published in Nature, Science, Cell
Plexium founding team
Proposed and developed a POC
of the platform for optogenetic Nav1.7
drug screening in collaboration
with Vertex Pharmaceuticals inc.
Pavel Chubukov, PhD
Founder, stand-in CTO
Ph.D. Scripps Research
Program Manager, Construction Engineer
Naval Mobile Construction Battalion Platoon Commander
Public Works Officer, Deep Sea Diving Officer, Ocean Survey Officer at Navy Civil Engineer Corps
Datacenter Engineer, at Veterans Affairs National Datacenter Operations and Logistics
Acquisition Liaison at the Bureau of Ocean Energy Management
Benjamin Queener
Founder, interim CEO
St. Jude Children’s Research Hospital
Sr. Researcher: Hematology, Tsai Lab
Gene therapy technology development
1859 Advanced Research
Vertex Pharmaceuticals
partnership scientist
Plexium founding team
Yousif Slaiwa
Founder, Director
Advancing therapeutic bioconjugate discovery and manufacturing
A site-selective, orthogonal, and scalable bioconjugation technology for faster, more precise discovery
and manufacturing of biologics
Protected by wholly owned IP (provisional patent filed)
Founded by researchers
from Scripps Research
& industry experts
Contact us
We are a deep-tech biotechnology company
developing next-generation tools
for site-specific bioconjugation.
Our mission is to give scientists
full control over where and how payloads are attached — unlocking precision, speed, and scale
in biologics development.
Born out of rigorous scientific research and engineering principles, our team bridges the gap between biology and manufacturability, enabling what others cannot: robust, scalable expression
of novel biomolecules in a fraction of the time.
[About Us]
Published in Nature, Science, Cell,
Plexium founding team
Proposed and developed a POC
of the platform for optogenetic Nav1.7
drug screening in collaboration
with Vertex Pharmaceuticals inc.
Pavel Chubukov, PhD
Founder, stand-in CTO
Ph.D. Scripps Research
St. Jude Children’s Research Hospital
Sr. Researcher: Hematology
Gene therapy technology development
1859 Advanced Research
Vertex Pharmaceuticals
partnership scientist
Plexium founding team
Yousif Slaiwa
Founder, Director
Program Manager, Construction Engineer
Naval Mobile Construction Battalion Platoon Commander
Public Works Officer, Deep Sea Diving Officer, Ocean Survey Officer at Navy Civil Engineer Corps
Datacenter Engineer, at Veterans Affairs National Datacenter Operations and Logistics
Acquisition Liaison at the Bureau
of Ocean Energy Management
Benjamin Queener
Founder, interim CEO
[Our science]
We believe bioconjugation should be engineered,
not improvised.
[Compared to conventional methods]
[Our platform offers:]
You know where the payload goes
—every time
Quantitative
Site-selectivity
Compatible with other conjugation strategies without cross-reaction
Bio-Orthogonality
Faster lead molecule identification and production cycles
Speed & Efficiency
Eliminate guesswork, increase precision, and reduce cost
Homogeneity & Control
Feature
Scalability
Yield
Site-specificity
Our Platform
Traditional Methods
Compatibility
Limited
Inconsistent
Hard to reproduce
Limited
Precise
Robust
Designed for manufacturing
Orthogonal to other pathways
Antibody-drug conjugates
(ADCs)
Custom-bioconjugates
modified cytokines
therapeutic viral particles
manufacturable biosimilars
for short half life
radionuclide delivery
Ultra-fast payload conjugation
[Applications]
Our platform enables transformative capabilities across multiple therapeutic categories:
Let’s build the next breakthrough together.
Contact us to explore collaboration.
Contact our team
[Careers]
[Contacts]
We’re always looking for talented scientists, engineers, and builders who want to reimagine what’s possible.
Share your details, and we’ll gladly contact you to discuss your inquiries or ideas.
We don’t post traditional job openings,
because we’re building something non-traditional.
If you’re excited by our mission, reach out
and tell us how you'd like to contribute.
Send your resume and note to info@nodon.bio or use the contact form below.
Send your resume and note to info@nodon.bio or use the contact form below.
Antibody-drug conjugates
(ADCs)
Custom-bioconjugates
modified cytokines
therapeutic viral particles
manufacturable biosimilars
for short half life
radionuclide delivery
Ultra-fast
payload conjugation
We are a deep-tech biotechnology company
developing next-generation tools
for site-specific bioconjugation.
Our mission is to give scientists
full control over where and how payloads are attached — unlocking precision, speed, and scale
in biologics development.
Born out of rigorous scientific research and engineering principles, our team bridges the gap between biology and manufacturability, enabling what others cannot: robust, scalable expression of novel biomolecules in a fraction of the time.
[About Us]
[Our science]
We believe bioconjugation should be engineered, not improvised.
[Compared to conventional methods]
[Our platform offers:]
[Applications]
[Careers]
[Contacts]
Advancing therapeutic bioconjugate discovery and manufacturing
A site-selective, orthogonal, and scalable bioconjugation technology for faster, more precise discovery
and manufacturing of biologics
Contact us
Incubating in Austin, TX
at ACC Bioscience Incubator
Protected by wholly owned IP (provisional patent filed)
Founded by researchers
from Scripps Research
& industry experts
You know where the payload goes—every time.
Quantitative
Site-selectivity
Compatible with other conjugation strategies without cross-reaction.
Bio-Orthogonality
Faster lead molecule identification and production cycles.
Speed & Efficiency
Eliminate guesswork, increase precision, and reduce cost.
Homogeneity & Control
Our platform enables transformative capabilities across multiple therapeutic categories:
We’re always looking for talented scientists, engineers, and builders who want to reimagine
what’s possible.
Share your details, and we’ll gladly contact you to discuss your inquiries or ideas.
We don’t post traditional job openings,
because we’re building something non-traditional.
If you’re excited by our mission, reach out
and tell us how you'd like to contribute.
Send your resume and note to info@nodon.bio or use the contact form below
Let’s build the next breakthrough together.
Contact us to explore collaboration.
Feature
Compatibility
Scalability
Yield
Site-specificity
Our Platform
Traditional Methods
Limited
Inconsistent
Hard to reproduce
Limited
Precise
Robust
Designed for manufacturing
Orthogonal to other pathways
Published in Nature, Science, Cell
Plexium founding team
Proposed and developed a POC
of the platform for optogenetic Nav1.7
drug screening in collaboration
with Vertex Pharmaceuticals inc.
Pavel Chubukov, PhD
Founder, stand-in CTO
Ph.D. Scripps Research
Program Manager, Construction Engineer
Naval Mobile Construction Battalion Platoon Commander
Public Works Officer, Deep Sea Diving Officer, Ocean Survey Officer at Navy Civil Engineer Corps
Datacenter Engineer, at Veterans Affairs National Datacenter Operations and Logistics
Acquisition Liaison at the Bureau of Ocean Energy Management
Benjamin Queener
Founder, interim CEO
St. Jude Children’s Research Hospital
Sr. Researcher: Hematology, Tsai Lab
Gene therapy technology development
1859 Advanced Research
Vertex Pharmaceuticals
partnership scientist
Plexium founding team
Yousif Slaiwa
Founder, Director